WHO ICTRP trial
Addition of binimetinib after refractory to encorafenib and cetuximab in…
JPRN-jRCTs031210510 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCTs031210510 |
|---|---|
| Public title | Addition of binimetinib after refractory to encorafenib and cetuximab in patients with BRAF V600E-mutant metasta tic colorectal cancer |
| Scientific title | A phase II study of encorafenib +binimetinib +cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer after refractory to encorafenib +cetuximab - BAYONET |
| Primary sponsor | Bando Hideaki |
| Secondary sponsors | Yoshino Takayuki |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Conditions | Unresectable, advanced or recurrent colorectal cancer with BRAF V600E mutation |
| Interventions | Encorafenib 300 mg once daily Binimetinib 45 mg twice daily Cetuximab 400 mg/m^2 Day 1, 250 mg/m^2 Day 8, 15, 22 (250 mg/m^2 from Cycle 2 later) These treatments are repeated every 28 days in one cycle. |
| Registration date | Jan 1, 2022 |
| Target size | 30 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: